Helping patients reclaim a life of possibility
Chimeric antigen receptor (CAR) T-cell therapy is a treatment that uses genetically modified immune cells (T-cells) to treat myeloma. While clinical studies have demonstrated the strong efficacy of CAR T-cell therapies in this disease, many patients experience side effects that can persist for months or years after treatment. To inform myeloma patients and the myeloma…
At the 2024 American Society of Hematology (ASH) Annual Meeting, Myeloma Patients Europe (MPE) interviewed experts about the most interesting studies and abstracts in myeloma and AL amyloidosis research that were presented during the conference. Our series of interviews highlights key findings and their impact on patient care: 🎥 Dr. Laurent Garderet discusses the IFM2017-03…
The American Society of Hematology (ASH) Annual Meeting, the world’s largest haematology conference, will take place from 7 – 10 December in San Diego, United States. It is a very exciting event for the myeloma and AL amyloidosis clinical and patient community, with all the results from the latest and most important research being presented.…
Every myeloma patient has a story to tell. And every story captures a very personal experience of our incurable blood cancer. Living with myeloma is more than navigating the physical challenges of illness and treatment. It is also about finding a path through mental health issues: toxic thoughts, rollercoaster emotions and imperilled well-being. Because myeloma…
The European Commission has approved marketing authorisation extension for the CAR-T treatment ciltacabtagene autoleucel (Carvytki®), also known as cilta-cel, for use in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD – such as lenalidomide and pomalidomide) and a proteasome inhibitor (PI – such as bortezomib or carfilzomib), have demonstrated disease progression…